Sugi Predict

Sugi Predict / Compounds / SCHEMBL6174183

SCHEMBL6174183

SCHEMBL6174183

Cc1nnnn1-c1ccc(/C(=C\C2CCCC2)C(=O)O)cc1C(F)(F)F

nearest known ligand 0.38

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ NOTUM Q6P988 1/20 0.38
▸ SMURF1 Q9HCE7 1/20 0.35
▸ ADCY8 P40145 1/20 0.35
▸ ADCY1 Q08828 1/20 0.35
▸ TAS1R3 Q7RTX0 1/20 0.33
▸ TAS1R1 Q7RTX1 1/20 0.33
▸ TAS1R2 Q8TE23 1/20 0.33
▸ KCNJ1 P48048 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ SCN9A Q15858 2/20 0.33
▸ LRRK2 Q5S007 2/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ S1PR1 P21453 2/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ SLC9A1 P19634 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6174191 1.00 NOTUM (0.38) NOTUMSMURF1ADCY8ADCY1TAS1R3
SCHEMBL2658917 0.89 SMURF1 (0.39) NOTUMSMURF1ADCY8ADCY1TAS1R3
SCHEMBL2658911 0.89 SMURF1 (0.39) NOTUMSMURF1ADCY8ADCY1TAS1R3
SCHEMBL6175122 0.88 NOTUM (0.35) NOTUMSMURF1ADCY8ADCY1TAS1R3
SCHEMBL6175131 0.88 NOTUM (0.35) NOTUMSMURF1ADCY8ADCY1TAS1R3
SCHEMBL6176497 0.86 F10 (0.35) KCNJ1LMNAL3MBTL1
SCHEMBL6176504 0.86 F10 (0.35) KCNJ1LMNAL3MBTL1
SCHEMBL6174778 0.84 CNR1 (0.35) SMURF1KCNJ1LMNAL3MBTL1
SCHEMBL6174771 0.84 CNR1 (0.35) SMURF1KCNJ1LMNAL3MBTL1
SCHEMBL6173925 0.83 CNR1 (0.36) SMURF1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1311504-B1 TETRAZOLYL-PHENYL ACETAMIDE GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2005-06-15 — — EP disclosed
US-6441180-B1 TO INCREASE INSULIN SECRETION, WHICH MAKES THEM USEFUL FOR TREATING TYPE II DIABETES HOFFMANN-LA ROCHE INC. 2002-08-27 — — US disclosed
US-20020065275-A1 Tetrazolyl-phenyl actamide glucokinase activators SIDDURI ACHYUTHARAO (US) 2002-05-30 — — US disclosed
US-6388088-B1 ANTIDIABETIC AGENTS HOFFMAN-LA ROCHE INC. 2002-05-14 — — US disclosed
US-6369232-B1 ANTIDIABETIC AGENTS HOFFMANN-LA ROCHE INC. 2002-04-09 — — US disclosed
US-20020035267-A1 Tetrazolyl-phenyl acetamide glucokinase activators SIDDURI ACHYUTHARAO (US) 2002-03-21 — — US disclosed
US-20020035266-A1 Tetrazolyl-phenyl acetamide glucokinase activators SIDDURI ACHYUTHARAO (US) 2002-03-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020035267-A1 Tetrazolyl-phenyl acetamide glucokinase activators GCKR, GCK, PCK1 NOTUM 1489/4885SMURF1 4717/4885ADCY8 501/4885
US-20020035266-A1 Tetrazolyl-phenyl acetamide glucokinase activators GCKR, GCK, PCK1 NOTUM 1489/4885SMURF1 4717/4885ADCY8 501/4885
US-20020065275-A1 Tetrazolyl-phenyl actamide glucokinase activators GCKR, GCK, PFKL NOTUM 1459/4885SMURF1 4519/4885ADCY8 548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.